Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Completed PHASE1 INTERVENTIONAL NCT00461448

A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Rheumatoid arthritis is the paradigmatic immune-mediated inflammatory arthropathy. With respect to rheumatoid arthritis (RA), patients have been described as having inappropriately low spontaneous and stimulated cortisol secretion levels. Serum cortisol levels are decreased in RA patients who are taking prednisolone. Also, in patients RA, of longer duration, glucocorticoid receptor (GR) down-regulation has been reported without any change in cortisol levels. There is a reduced capacity for local reactivation of cortisone to cortisol in RA synovial cells. It is noteworthy that since synthetic glucocorticoids also use same reactivation shuttle (the cortisol-cortisone shuttle), the results also apply to therapeutic glucocorticoids. Glucocorticoids are widely used to treat chronic inflammatory conditions including rheumatoid arthritis. Prednisolone has a greater effect than non-steroidal, anti-inflammatory drugs on joint tenderness and pain, whereas the difference in grip strength was not significant. There are no qualitative differences between the effects of endogenous cortisol and exogenously applied synthetic glucocorticoids, since all effects are transmitted via the same receptor. Cortisol, on the other hand, plays a major role in normal potassium homeostasis. Recent studies have highlighted a role for diet, with suggestions that diets high in caffeine, low in antioxidants and high in red meat may contribute to an increased risk for the development of rheumatoid arthritis. Higher intakes of complex carbohydrates, dietary fiber, magnesium, folic acid, vitamin C and E, carotenoids and other phytochemicals have been shown to offer distinct advantages compared to diets containing meat and other foods of animal origin. The relation of a potassium deficiency to RA is much less well documented. The first person to definitively link potassium with arthritis was DeCoti Marsh. LaCelle, Morgan \& Atwater found that the cells of 50 arthritic patients were 30 to 50% lower than healthy people. Our current clinical trial (clinical trial no NCT00399282) shows that most of patients with RA do not have enough potassium intake. This condition may contribute to a subclinical lower serum cortisol, although there is possibility that cortisol serum levels might be unchanged due to a sufficient "cortisol homeostasis" and "potassium homeostasis".

Detailed Description

This study examines the hypothesis if patients with rheumatoid arthritis evaluate, or rate, symptom improvements after potassium supplementation (as KCl). Participants will undergo the following tests and procedures: Medical history and physical examination. Measurements of weight and height. Blood sample collections for clinical and research purposes. Quality of life questionnaires. We therefore examined the hypothesis that examines effect of an orally administrated grape juice enriched (GJE) with 6000 mg potassium (as KCl) compared with that of a placebo grape juice (PGJ) on serum indices (cortisol, ACTH, aldosterone, creatinine, pH, Na, K), urinalysis (urea, uric acid, K, Na, creatinine, pH), GFR corrected by body surface area, ESR, CRP, RF, pain, quality of life, and disease activity in a case-controlled double-blind protocol in patients with RA with an established low dietary potassium intake to further investigate endogenous cortisol secretion and consequent possible relief. Clinical (like Disease Activity, Pain) variables, along with the Quality of Life, and Biochemical Indices will be compared in two groups of patients after 28 days of oral GJE and PJE administration.

Interventions

Name: Potassium supplement
Type: DIETARY_SUPPLEMENT
Description: Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.

Primary Outcomes

Measure: Patient's dietary and supplement potassium intake (combined technique: food frequency questionnaire, 24 hour food-recall, food record), serum potassium
TimeFrame: within the 28 days (plus or minus 2 days)
Description:
Measure: Disease Activity Score (DAS28, 28-joint count) at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Patient's global assessment of disease activity (0 to 10 cm visual analog scale: 0, symptom free; 10, very severe) at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Patient's visual analogue scale (VAS) for pain at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Duration of morning stiffness (in minutes) at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Joint pain intensity, on a visual analogue scale (VAS) for pain (0 = no pain to 100mm =severe pain) at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Onset of fatigue (in minutes) after walking at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Ritchie's articular index for pain joints at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Right and left grip strength (in mmHg) measured with a sphygmomanometer cuff inflated to 20 mmHg at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:
Measure: Classification of functional status in RA according to revised criteria of the American College of Rheumatology at Patient's global assessment of disease activity (0 to 10 cm visual analog scale: 0, symptom free; 10, very severe) at d 0, 28
TimeFrame: within the first 28 days (plus or minus 2 days)
Description:

Trial Information

NCT ID

NCT00461448

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Shahid Beheshti University of Medical Sciences

Last Updated

December 15, 2025